Gateway 2011:Natoli Engineering Company, Inc - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gateway 2011:Natoli Engineering Company, Inc

Your online Gateway to Natoli Engineering Company, Inc. in 2011

28 Research Park Circle
St. Charles, MO 63304
Fax: 636-926-8910

About Natoli Engineering Company, Inc.

Natoli Tooling

Natoli has provided top quality tablet compression tooling for over 35 years and have grown to offer an extensive line of products and services to assist all stages of the tablet production process. No other company in the industry offers a more complete range of products and services, and their commitment to innovation and excellence has earned them an international reputation for high quality and reliability.


Natoli offers world-renowned tablet compression tooling, tablet presses, press refurbishing services, replacement parts and turrets, punch inspection systems and software, Light Induced Fluorescence (LIF) Sensor, technical training courses, and an all-new Tablet Compression Accessories Catalog.

Light Induced Fluorescence (LIF) Sensor

Natoli Engineering Company, Inc. invites you to join us at Interphex 2011. We will be showcasing our newest product, the Light Induced Fluorescence (LIF) Sensor. As a valuable new analytical process technology, the LIF Sensor was designed for process cleaning validation, liquid applications and blend uniformity endpoint monitoring. Stop by our booth to see a product demonstration and speak with one of our experts about what the LIF Sensor can do for you!


For more information:  



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here